Edgewise Therapeutics, Inc. (EWTX) shareholders
Close on Nov 17, 2026Market cap $4.57BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp Vi LLC (14.10%) | 15,252,867 | 14.50% | 13D (active) amendment | May 9, 2025 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 10,428,437 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Paradigm BioCapital Advisors GP LLC Joint filing with Paradigm BioCapital Advisors LP (9.50%), Senai Asefaw, M.D. (9.50%) and 1 more | 10,215,455 | 9.50% | 13G (passive) amendment | Jun 30, 2026 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (7.80%), Peter Kolchinsky (7.80%) and 1 more | 8,392,730 | 7.80% | 13G (passive) amendment | Jun 30, 2026 |
| Baker Bros. Advisors LP Joint filing with Baker Bros. Advisors (GP) LLC (6.90%), Julian C. Baker (6.90%) and 1 more | 7,305,940 | 6.90% | 13G (passive) amendment | Jun 30, 2025 |
| Senai Asefaw, M.D. Joint filing with Paradigm BioCapital Advisors LP (6.20%), Paradigm BioCapital Advisors GP LLC (6.20%) and 1 more | 6,541,210 | 6.20% | 13G (passive) amendment | Dec 31, 2025 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (6.10%), Joseph Edelman (6.10%) | 6,395,546 | 6.10% | 13G (passive) amendment | Mar 31, 2025 |
| Janus Henderson Group PLC | 5,915,556 | 5.50% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 5,824,866 | 5.50% | 13G (passive) amendment | Jun 30, 2025 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (5.50%), Perceptive Life Sciences Master Fund, Ltd. (5.50%) | 5,164,487 | 5.50% | 13G (passive) | Feb 13, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of EWTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 15,518,492 | 14.29% | $630.52M | – | 11.68% |
| Paradigm Biocapital Advisors LP | 10,215,455 | 9.41% | $415.05M | +2,850,417 | 7.77% |
| Ra Capital Management, L.P. | 8,392,730 | 7.73% | $341.00M | −2,035,707 | 2.96% |
| BlackRock, Inc. | 6,606,336 | 6.08% | $268.42M | +133,345 | 0.00% |
| Jupiter Topco LLC | 6,075,331 | 5.59% | $246.95M | New | 0.10% |
| FMR LLC | 5,489,135 | 5.05% | $223.02M | +4,472,083 | 0.01% |
| Novo Holdings A/S | 5,350,000 | 4.93% | $217.37M | – | 12.62% |
| Driehaus Capital Management LLC | 4,728,623 | 4.35% | $192.12M | +250,681 | 1.11% |
| Perceptive Advisors LLC | 4,373,974 | 4.03% | $177.71M | −50,000 | 2.67% |
| Vanguard Capital Management LLC | 3,860,670 | 3.55% | $156.86M | +72,509 | 0.00% |
| Baker Bros. Advisors LP | 3,701,719 | 3.41% | $150.40M | −2,874,221 | 0.75% |
| Siren, L.L.C. | 3,184,629 | 2.93% | $129.39M | −1,245,634 | 2.62% |
| Cormorant Asset Management, LP | 2,510,000 | 2.31% | $101.98M | −750,000 | 5.23% |
| Geode Capital Management, LLC | 2,174,051 | 2.00% | $88.35M | +384,232 | 0.00% |
| Alliancebernstein L.P. | 2,119,024 | 1.95% | $66.75M | +396,855 | 0.02% |
| Integral Health Asset Management, LLC | 2,000,000 | 1.84% | $81.26M | +400,000 | 3.21% |
| Braidwell LP | 1,996,965 | 1.84% | $81.14M | −350,618 | 3.00% |
| Morgan Stanley | 1,948,597 | 1.79% | $79.17M | −297,431 | 0.00% |
| State Street Corp | 1,827,927 | 1.68% | $74.27M | +111,104 | 0.00% |
| Mpm Bioimpact LLC | 1,620,780 | 1.49% | $65.85M | −39,916 | 4.02% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 225 | 119M | 100.0% | 42 / 83 | 73 / 26 | 22M | 15M |
| Q1 2026 | 214 | 119M | 100.0% | 44 / 66 | 65 / 25 | 12M | 10M |
| Q4 2025 | 199 | 122M | 100.0% | 48 / 69 | 54 / 20 | 18M | 7M |
| Q3 2025 | 173 | 112M | 100.0% | 18 / 59 | 61 / 23 | 4M | 11M |
| Q2 2025 | 178 | 119M | 100.0% | 30 / 88 | 39 / 41 | 22M | 9M |
| Q1 2025 | 192 | 106M | 97.3% | 33 / 70 | 60 / 38 | 14M | 7M |
| Q4 2024 | 200 | 99M | 91.2% | 44 / 70 | 64 / 20 | 10M | 12M |
| Q3 2024 | 177 | 102M | 93.5% | 53 / 57 | 45 / 15 | 21M | 15M |
| Q2 2024 | 140 | 102M | 93.7% | 33 / 59 | 30 / 21 | 16M | 7M |
| Q1 2024 | 129 | 92M | 85.1% | 32 / 60 | 28 / 19 | 33M | 21M |
| Q4 2023 | 116 | 80M | 73.6% | 38 / 44 | 19 / 7 | 13M | 1M |
| Q3 2023 | 85 | 68M | 63.0% | 9 / 41 | 17 / 18 | 2M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
219 funds held EWTX in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of EWTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,902,230 | 2.67% | $117.92M | 0.01% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,940,531 | 1.79% | $66.29M | 0.03% | May 31, 2026 |
| iShares Russell 2000 ETF | 1,835,831 | 1.69% | $74.59M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 864,638 | 0.80% | $35.13M | 0.04% | Jun 30, 2026 |
| Small Cap Growth Fund | 856,214 | 0.79% | $32.90M | 0.59% | Jul 31, 2026 |
| Victory Pioneer Select Mid Cap Growth Fund | 795,789 | 0.73% | $27.18M | 1.43% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 782,053 | 0.72% | $30.05M | 0.09% | Jul 31, 2026 |
| Select Biotechnology Portfolio | 699,425 | 0.64% | $23.89M | 0.45% | May 31, 2026 |
| Janus Henderson Global Life Sciences Fund | 677,076 | 0.62% | $27.51M | 0.47% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 660,219 | 0.61% | $26.82M | 0.17% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 642,530 | 0.59% | $24.69M | 0.28% | Jul 31, 2026 |
| iShares Biotechnology ETF | 556,093 | 0.51% | $22.59M | 0.25% | Jun 30, 2026 |
| AB Small Cap Growth Portfolio | 533,585 | 0.49% | $21.68M | 0.69% | Jun 30, 2026 |
| Driehaus Small Cap Growth Fund | 522,169 | 0.48% | $21.22M | 1.32% | Jun 30, 2026 |
| Ab Discovery Growth Fund, Inc. | 489,862 | 0.45% | $19.90M | 0.69% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Alan J. Russell | Chief Scientific Officer, Director | 31,856 | 0.03% | Aug 17, 2026 |
| Kevin Koch | President and CEO, Director | 391,272 | 0.36% | Aug 14, 2026 |
| Michael Nofi | Chief Financial Officer | 6,495 | 0.01% | Nov 10, 2026 |
| Behrad Derakhshan | Chief Business Officer | 29,426 | 0.03% | Aug 17, 2026 |
| John R. Moore | General Counsel | 15,995 | 0.01% | Aug 17, 2026 |
| Joanne M. Donovan | CMO | 8,625 | 0.01% | Aug 17, 2026 |
| Robert Blaustein | Chief Development Officer | – | – | Aug 14, 2025 |
| R. Michael Carruthers | Chief Financial Officer | 86,162 | 0.08% | Aug 14, 2025 |
| Marc Semigran | Chief Development Officer | 6,716 | 0.01% | Dec 27, 2024 |
| Jonathan C. Fox | Director | 25,141 | 0.02% | Oct 2, 2026 |
| Jonathan D. Root | Director | 15,625 | 0.01% | Jul 17, 2026 |
| Laura Brege | Director | – | – | Jun 17, 2026 |
| Peter A. Thompson | Director, 10% owner | 443,792 | 0.41% | Jun 17, 2026 |
| Arlene Morris | Director | – | – | Jun 17, 2026 |
| Christopher Nathan Martin | Director | – | – | Jun 16, 2026 |
| Badreddin Edris | Director | 96,760 | 0.09% | Jun 16, 2026 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 14,809,075 | 13.64% | Apr 4, 2025 |
| Advisors Llc Orbimed | Director, 10% owner | 319,599 | 0.29% | Apr 4, 2025 |
| Capital GP VI LLC OrbiMed | Director, 10% owner | 14,436,497 | 13.29% | Apr 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Nofi Chief Financial Officer | Nov 10, 2026 | Sale | −4,442 | $45.43 | $201.79K | 6,495 |
| Michael Nofi Chief Financial Officer | Nov 10, 2026 | Option exercise | +10,937 | – | – | 10,937 |
| Jonathan C. Fox Director | Oct 1, 2026 | Award | +308 | – | – | 25,141 |
| Joanne M. Donovan CMO | Aug 13, 2026 | Sale(10b5-1 plan) | −2,919 | $43.41 | $126.71K | 8,625 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Option exercise | +5,781 | – | – | 29,426 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Option exercise | +7,500 | – | – | 36,926 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Sale | −2,171 | $43.79 | $95.07K | 34,755 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Sale | −304 | $44.50 | $13.53K | 34,451 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Sale | −2,475 | $43.70 | $108.16K | 31,826 |
| Behrad Derakhshan Chief Business Officer | Aug 12, 2026 | Sale | −150 | $44.44 | $6.67K | 34,301 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Sale | −913 | $44.33 | $40.47K | 52,488 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Option exercise | +17,969 | – | – | 48,584 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Option exercise | +21,875 | – | – | 70,459 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Sale | −8,782 | $43.64 | $383.25K | 61,677 |
| Kevin Koch President and CEO, Director | Aug 12, 2026 | Sale | −8,276 | $43.66 | $361.33K | 53,401 |
| John R. Moore General Counsel | Aug 12, 2026 | Option exercise | +5,781 | – | – | 15,995 |
| John R. Moore General Counsel | Aug 12, 2026 | Sale | −2,419 | $43.80 | $105.95K | 17,697 |
| John R. Moore General Counsel | Aug 12, 2026 | Sale | −99 | $44.50 | $4.41K | 20,116 |
| John R. Moore General Counsel | Aug 12, 2026 | Sale | −59 | $44.41 | $2.62K | 20,215 |
| John R. Moore General Counsel | Aug 12, 2026 | Option exercise | +6,718 | – | – | 22,713 |
| John R. Moore General Counsel | Aug 12, 2026 | Sale | −2,439 | $43.81 | $106.85K | 20,274 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Sale | −2,273 | $43.68 | $99.28K | 31,856 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Sale | −390 | $44.46 | $17.34K | 31,466 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Option exercise | +5,781 | – | – | 30,336 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Option exercise | +7,031 | – | – | 37,367 |
| Alan J. Russell Chief Scientific Officer, Director | Aug 12, 2026 | Sale | −3,238 | $43.68 | $141.44K | 34,129 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Option exercise | +5,781 | – | – | 11,035 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Option exercise | +7,031 | – | – | 18,066 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Sale(10b5-1 plan) | −2,839 | $43.78 | $124.29K | 15,227 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Sale(10b5-1 plan) | −2,779 | $43.71 | $121.47K | 12,448 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Sale(10b5-1 plan) | −104 | $44.43 | $4.62K | 12,344 |
| Joanne M. Donovan CMO | Aug 12, 2026 | Sale(10b5-1 plan) | −800 | $44.52 | $35.62K | 11,544 |
| Alan J. Russell Chief Scientific Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −130,352 | $39.41 | $5.14M | 94,203 |
| Alan J. Russell Chief Scientific Officer, Director | Jul 1, 2026 | Option exercise | +130,352 | $0.45 | $58.66K | 154,907 |
| Alan J. Russell Chief Scientific Officer, Director | Jul 1, 2026 | Option exercise | +69,648 | $0.18 | $12.54K | 224,555 |
| Alan J. Russell Chief Scientific Officer, Director | Jul 1, 2026 | Sale(10b5-1 plan) | −69,648 | $39.41 | $2.74M | 24,555 |
| Jonathan C. Fox Director | Jul 1, 2026 | Award | +319 | – | – | 24,833 |
| Joanne M. Donovan CMO | May 5, 2026 | Option exercise | +50,000 | $7.08 | $354.00K | 54,367 |
| Joanne M. Donovan CMO | May 5, 2026 | Sale(10b5-1 plan) | −50,000 | $38.57 | $1.93M | 4,367 |
| Joanne M. Donovan CMO | May 4, 2026 | Sale(10b5-1 plan) | −5,230 | $31.29 | $163.65K | 4,367 |
| Jonathan C. Fox Director | Apr 1, 2026 | Award | +339 | – | – | 24,514 |
| Joanne M. Donovan CMO | Apr 1, 2026 | Sale(10b5-1 plan) | −28,662 | $32.31 | $926.07K | 9,597 |
| Joanne M. Donovan CMO | Apr 1, 2026 | Option exercise | +28,662 | $7.08 | $202.93K | 38,259 |
| Joanne M. Donovan CMO | Mar 31, 2026 | Option exercise | +21,338 | $7.08 | $151.07K | 30,935 |
| Joanne M. Donovan CMO | Mar 31, 2026 | Sale(10b5-1 plan) | −21,338 | $32.12 | $685.38K | 9,597 |
| Joanne M. Donovan CMO | Mar 27, 2026 | Sale(10b5-1 plan) | −6,735 | $30.98 | $208.65K | 9,597 |
| Joanne M. Donovan CMO | Mar 27, 2026 | Sale(10b5-1 plan) | −9,623 | $30.98 | $298.12K | 16,332 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −7,605 | $29.44 | $223.89K | 96,760 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −17,236 | $29.44 | $507.43K | 104,365 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −10,463 | $29.44 | $308.03K | 86,297 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −66,477 | $29.44 | $1.96M | 19,820 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +66,477 | $1.93 | $128.30K | 127,686 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +13,690 | $0.39 | $5.34K | 33,510 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +17,236 | $0.64 | $11.03K | 50,746 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +10,463 | $1.93 | $20.19K | 61,209 |
| Badreddin Edris Director | Jan 21, 2026 | Option exercise | +7,605 | $0.71 | $5.40K | 135,291 |
| Badreddin Edris Director | Jan 21, 2026 | Sale(10b5-1 plan) | −13,690 | $29.44 | $403.03K | 121,601 |
| Jonathan C. Fox Director | Jan 2, 2026 | Award | +473 | – | – | 24,175 |
| Alan J. Russell Chief Scientific Officer, Director | Nov 12, 2025 | Option exercise | +100,000 | $0.18 | $18.00K | 123,400 |
| Alan J. Russell Chief Scientific Officer, Director | Nov 12, 2025 | Sale | −100,000 | $21.12 | $2.11M | 23,400 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Edgewise Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,000 shares on Aug 31, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Joanne M. Donovan Officer | Aug 13, 2026 | 2,919 | $127.15K | Aug 13, 2026 | Restricted Stock Units |
| Alan J. Russell Director, Officer | Jul 1, 2026 | 200,000 | $8.13M | Jul 1, 2026 | Exercise of Stock Options |
| Joanne M. Donovan Officer | May 5, 2026 | 50,000 | $1.57M | May 5, 2026 | Exercise of Stock Options |
| Joanne M. Donovan Officer | Mar 27, 2026 | 71,588 | $2.27M | Mar 27, 2026 | Exercise of Stock Options |
| Badreddin Edris Director | Jan 21, 2026 | 115,471 | $3.35M | Jan 21, 2026 | Stock Option Exercise |
| R. Michael Carruthers Officer | Jan 20, 2026 | 183,867 | $5.17M | Jan 20, 2026 | Exercise of options under a registered plan |
| R. Michael Carruthers Officer | Jan 15, 2026 | 180,872 | $4.80M | Jan 15, 2026 | Exercise of options under a registered plan |
| R. Michael Carruthers Officer | Dec 29, 2025 | 116,665 | $3.04M | Dec 26, 2025 | Exercise of options under a registered plan |
| R. Michael Carruthers Officer | Nov 17, 2025 | 70,000 | $1.57M | Nov 17, 2025 | Previously Exercised Options |
| Alan J. Russell Officer, Director | Nov 12, 2025 | 100,000 | $2.11M | Nov 12, 2025 | Exercise of options under a registered plan |
| Alan J. Russell Officer, Director | Aug 26, 2025 | 100,000 | $1.46M | Aug 26, 2025 | Exercise of options under a registered plan |
| Behrad Derakhshan Officer | Feb 5, 2025 | 40,000 | $1.19M | Feb 5, 2025 | NQ Stock Option Exercise |
| Kevin Koch Director, Officer | Feb 5, 2025 | 51,181 | $1.51M | Feb 5, 2025 | Exercise of Stock Options |
| Alan J. Russell Director, Officer | Feb 5, 2025 | 100,000 | $2.95M | Feb 5, 2025 | Exercise of Stock Options |
| Joanne M. Donovan Officer | Jan 28, 2025 | 25,000 | $696.25K | Jan 28, 2025 | Exercise of Stock Options |
See a number that looks wrong?